The idea behind Veltio Pharma® was born from a simple but powerful insight, a natural and renewable material like porous cellulose could enable the formulation of poorly soluble drugs. In 2018, Albert Mihranyan founded Veltio Pharma with a mission to improve how solid oral medicines are developed by addressing one of the pharma industry's persistent challenges: poor solubility and thereby low bioavailability of drug candidates. The name Veltio comes from the Greek word βελτίο, meaning “better”, which reflects the company’s mission to develop better therapies, formulation processes, and ultimately, patient outcomes.

​

The path to that insight began more than two decades earlier. Albert earned his PhD in Pharmaceutics in 2005 and spent much of his scientific career at the Ångström Laboratory in Uppsala. Over the years, Albert came to believe that there had to be a smarter, more sustainable way to develop oral formulations. This belief led to the development of Veltio Pharma’s proprietary platform technology based on porous cellulose derived from algae, a biodegradable and renewable material. The approach simplifies the formulation process through fewer steps, while also offering improved drug solubility and thereby increased bioavailability, and greater environmental sustainability compared to conventional formulation methods.

​

Albert, who is currently Professor of Pharmaceutical Technology at Uppsala University, is the author of more than 90 peer-reviewed papers and the inventor of ten patent families. “It just comes to you as you work with passion and dedication,” Albert says of his discoveries. “A lot of it is chance and timing, but you also learn along the way. What matters most is staying professional and building trust, that’s how you move forward.” He adds, “But none of it happens without the right team.” Albert remains engaged as a board member, supporting Veltio’s long-term vision. With a new CEO leading the company and growing interest from industry partners, the team is now well positioned to enter the next phase to scale the business and delivering improved therapies to more patients.